Paul Emery

128.2k total citations · 32 hit papers
1.0k papers, 67.0k citations indexed

About

Paul Emery is a scholar working on Rheumatology, Hematology and Immunology. According to data from OpenAlex, Paul Emery has authored 1.0k papers receiving a total of 67.0k indexed citations (citations by other indexed papers that have themselves been cited), including 803 papers in Rheumatology, 256 papers in Hematology and 211 papers in Immunology. Recurrent topics in Paul Emery's work include Rheumatoid Arthritis Research and Therapies (691 papers), Systemic Lupus Erythematosus Research (316 papers) and Autoimmune and Inflammatory Disorders Research (245 papers). Paul Emery is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (691 papers), Systemic Lupus Erythematosus Research (316 papers) and Autoimmune and Inflammatory Disorders Research (245 papers). Paul Emery collaborates with scholars based in United Kingdom, United States and Netherlands. Paul Emery's co-authors include Philip G. Conaghan, Richard J. Wakefield, Philip O’Connor, Dennis McGonagle, E. Hensor, Josef S Smolen, Ferdinand C. Breedveld, Désirée van der Heijde, Ravinder N. Maini and Michael H. Weisman and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Investigation.

In The Last Decade

Paul Emery

971 papers receiving 64.8k citations

Hit Papers

Infliximab and Methotrexate in the Treatment of Rheumatoi... 1998 2026 2007 2016 2000 2004 1999 2018 2006 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis
    2000 2.4k citations Désirée van der Heijde, Paul Emery et al. profile →
  2. Efficacy of B-Cell–Targeted Therapy with Rituximab in Patients with Rheumatoid Arthritis
    2004 1.9k citations Paul Emery et al. profile →
  3. Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial
    1999 1.9k citations Paul Emery et al. profile →
  4. Rheumatoid arthritis
    2018 1.7k citations Josef S Smolen, Gerd R Burmester et al. profile →
  5. Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeks
    2006 1.3k citations Paul Emery, Maria Greenwald et al. profile →
  6. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized, controlled trial
    2004 940 citations Désirée van der Heijde, Josef S Smolen et al. profile →
  7. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial
    2008 866 citations Paul Emery et al. Annals of the Rheumatic Diseases profile →
  8. Treatment of Rheumatoid Arthritis by Selective Inhibition of T-Cell Activation with Fusion Protein CTLA4Ig
    2003 807 citations Paul Emery, Larry W. Moreland et al. profile →
  9. A simplified disease activity index for rheumatoid arthritis for use in clinical practice
    2003 795 citations Michael Schiff, Paul Emery et al. Lara D. Veeken profile →
  10. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double‐blind, placebo‐controlled, dose‐ranging trial
    2006 783 citations Paul Emery, Roy Fleischmann et al. profile →
  11. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist
    1998 767 citations Paul Emery et al. profile →
  12. New therapies for treatment of rheumatoid arthritis
    2007 754 citations Josef S Smolen, Paul Emery et al. profile →
  13. Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis
    2015 732 citations Maxime Dougados, Paul Emery et al. profile →
  14. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial
    2008 652 citations Paul Emery et al. profile →
  15. OMERACT Rheumatoid Arthritis Magnetic Resonance Imaging Studies. Core set of MRI acquisitions, joint pathology definitions, and the OMERACT RA-MRI scoring system.
    2003 602 citations Mikkel Østergaard, Philip G. Conaghan et al. PubMed profile →
  16. Double‐blind randomized controlled clinical trial of the interleukin‐6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate
    2006 601 citations Paul Emery et al. profile →
  17. An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis
    2008 590 citations Philip G. Conaghan, Mark Quinn et al. profile →
  18. EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)
    2006 566 citations Paul Emery, Gianfranco Ferraccioli et al. Annals of the Rheumatic Diseases profile →
  19. Effects of Abatacept in Patients with Methotrexate-Resistant Active Rheumatoid Arthritis
    2006 558 citations Larry W. Moreland, Paul Emery et al. profile →
  20. Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia
    2020 543 citations Paul Emery et al. profile →
  21. Psoriasis and Systemic Inflammatory Diseases: Potential Mechanistic Links between Skin Disease and Co-Morbid Conditions
    2010 538 citations Paul Emery et al. profile →
  22. Presence of significant synovitis in rheumatoid arthritis patients with disease‐modifying antirheumatic drug–induced clinical remission: Evidence from an imaging study may explain structural progression
    2006 536 citations Mark Quinn, Philip G. Conaghan et al. profile →
  23. The value of sonography in the detection of bone erosions in patients with rheumatoid arthritis: A comparison with conventional radiography
    2000 513 citations Richard J. Wakefield, Philip G. Conaghan et al. profile →
  24. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed
    2004 512 citations Maxime Dougados, Paul Emery et al. Annals of the Rheumatic Diseases profile →
  25. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial
    2013 502 citations Paul Emery et al. profile →
  26. A multicenter, prospective, randomized, double‐blind, placebo‐controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma
    2006 484 citations Paul Emery, Douglas J. Veale et al. profile →
  27. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: Findings of a fifty‐two–week, phase III, multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group study
    2008 465 citations Désirée van der Heijde, Robert Landewé et al. profile →
  28. Rheumatoid arthritis
    2023 350 citations Andrea Di Matteo, Paul Emery et al. profile →
  29. Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial
    2015 329 citations Laura C. Coates, Anna R. Moverley et al. profile →
  30. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study
    2016 301 citations Maxime Dougados, Désirée van der Heijde et al. Annals of the Rheumatic Diseases profile →
  31. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study
    2019 260 citations Paul Emery, Yoshiya Tanaka et al. profile →
  32. A Phase 2 Trial of Peresolimab for Adults with Rheumatoid Arthritis
    2023 74 citations Jay Tuttle, Edit Drescher et al. profile →

Peers

Paul Emery
Comparison fields: 5 of 192
  • Rheumatology 45.9k
  • Immunology 18.2k
  • Hematology 17.3k
  • Genetics 8.5k
  • Pathology and Forensic Medicine 7.7k
Replace Désirée van der Heijde with:
Désirée van der Heijde Netherlands
T. Huizinga Netherlands
Yehuda Shoenfeld Israel
Josef S Smolen Austria
Lars Klareskog Sweden
Iain B. McInnes United Kingdom
David Isenberg United Kingdom
Georg Schett Germany
Gene G. Hunder United States
Frank C. Arnett United States
Désirée van der Heijde Netherlands View profile →
Citations per field, relative to Paul Emery
Paul Emery · 1×
Citations per year, relative to Paul Emery
Paul Emery · 1×

Countries citing papers authored by Paul Emery

Since Specialization
Citations

This map shows the geographic impact of Paul Emery's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Emery with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Emery more than expected).

Fields of papers citing papers by Paul Emery

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul Emery. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Emery. The network helps show where Paul Emery may publish in the future.

Co-authorship network of co-authors of Paul Emery

This figure shows the co-authorship network connecting the top 25 collaborators of Paul Emery. A scholar is included among the top collaborators of Paul Emery based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul Emery. Paul Emery is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
# Work Indexed citations
1
Improving the arthritis component of the SLEDAI-2K
2024 ·Lara D. Veeken ·Khaled Mahmoud, Md Yuzaiful Md Yusof, Lee Suan Teh, Shah H.M. Khan, Chee‐Seng Yee, David D’Cruz, David Isenberg, Coziana Ciurtin, Philip G. Conaghan, Paul Emery, Christopher J Edwards, E. Hensor, Edward M Vital
1
2
POS0442 ENDOCITRULLINATION OF RA AUTOANTIGENS IS MORE ABUNDANT THAN C-TERMINAL CITRULLINATION IN THE GINGIVAL CREVICULAR FLUID OF ANTI-CCP POSITIVE AT-RISK INDIVIDUALS WITH PERIODONTAL DISEASE BUT NO SYNOVITIS
2023 ·Xin Yu, Svenja Hester, (unknown), Rajiv Chowdhury, (unknown), Robert W. Letton, Zhain Mustufvi, Josephine Meade, Thuy Do, Román Fischer, Kim S. Midwood, Paul Emery, Kulveer Mankia
1
3
POS0307 A PHASE 2 TRIAL OF PERESOLIMAB FOR ADULTS WITH RHEUMATOID ARTHRITIS
2023 ·Annals of the Rheumatic Diseases ·Jay Tuttle, Edit Drescher, Jesus Abraham Simón Campos, Paul Emery, Maria Greenwald, A. Kivitz, (unknown), Pia P. Yachi, (unknown), Ajay Nirula
1
4
Elevated Serum Levels of Zonulin Family Peptides in Anticitrullinated Protein Antibody–Positive At-Risk Individuals Without Arthritis
2023 ·The Journal of Rheumatology ·(unknown), K. Martinsson, Christopher Rooney, Jonas Wetterö, Kulveer Mankia, Paul Emery, Alf Kastbom
4
5
Lymphocyte subset phenotyping for the prediction of progression to inflammatory arthritis in anti-citrullinated-peptide antibody-positive at-risk individuals
2023 ·Lara D. Veeken ·(unknown), (unknown), Rekha Parmar, Kulveer Mankia, Farag Shuweihdi, Paul Emery, Frédérique Ponchel
6
6
Sustained Remission and Outcomes with Abatacept plus Methotrexate Following Stepwise Dose De-escalation in Patients with Early Rheumatoid Arthritis
2023 ·Rheumatology and Therapy ·Paul Emery, Yoshiya Tanaka, Vivian P. Bykerk, T. Huizinga, Gustavo Citera, Clifton O. Bingham, Subhashis Banerjee, Benjamin P. Soule, Marleen Nys, Seán Connolly, (unknown), (unknown), Robert Wong, Kuan‐Hsiang Gary Huang, R. Fleischmann
6
7
Patient-level factors predictive of interstitial lung disease in rheumatoid arthritis: a systematic review
2023 ·RMD Open ·Eric L. Matteson, Marco Matucci‐Cerinic, Michael Kreuter, Gerd R Burmester, Philippe Dieudé, Paul Emery, Yannick Allanore, Janet Pope, Dinesh Khanna
6
8
Ultrasound in the Management of Patients With Psoriatic Arthritis: Systematic Literature Review and Novel Algorithms for Pragmatic Use
2023 ·The Journal of Rheumatology ·Hélène Gouze, Marina Backhaus, P Bálint, Andrea Di Matteo, Walter Grassi, Annamaria Iagnocco, Esperanza Naredo, Richard J. Wakefield, Mikkel Østergaard, Paul Emery, Maria Antonietta D’Agostino
9
9
Initial glucocorticoid bridging in rheumatoid arthritis: does it affect glucocorticoid use over time?
2023 ·Annals of the Rheumatic Diseases ·(unknown), Patrick Verschueren, Maarten Boers, Paul Emery, Pascal H P de Jong, Robert Landewé, Willem F. Lems, Josef S Smolen, T. Huizinga, Cornelia F Allaart, Sytske Anne Bergstra
3
10
THU0175 REAL-WORLD EXPERIENCE OF SWITCHING FROM ORIGINATOR TO BIOSIMILAR RITUXIMAB IN RHEUMATOID ARTHRITIS
2020 ·Annals of the Rheumatic Diseases ·Andrew Melville, Md Yuzaiful Md Yusof, John Fitton, (unknown), Paul Emery, (unknown), S. Dass, Benazir Saleem
1
11
Comparing Psoriatic Arthritis Low-field Magnetic Resonance Imaging, Ultrasound, and Clinical Outcomes: Data from the TICOPA Trial
2019 ·The Journal of Rheumatology ·Philip Helliwell, Laura C. Coates, (unknown), (unknown), Anna R. Moverley, Jane Freeston, J. Nam, Robin Waxman, Paul Emery, Philip G. Conaghan
13
12
Low rates of radiographic progression of structural joint damage over 2 years of baricitinib treatment in patients with rheumatoid arthritis
2019 ·RMD Open ·Désirée van der Heijde, Michael Schiff, Yoshiya Tanaka, Li Xie, (unknown), Taeko Ishii, Marta Casillas, Robert Ortmann, Paul Emery
16
13
Cost‐Effectiveness of Tight Control of Inflammation in Early Psoriatic Arthritis: Economic Analysis of a Multicenter Randomized Controlled Trial
2017 ·Arthritis Care & Research ·John O’Dwyer, David Meads, Claire Hulme, Lucy McParland, Sarah Brown, Laura C. Coates, Anna R. Moverley, Paul Emery, Philip G. Conaghan, Philip Helliwell
10
14
Which joints and why do rheumatologists scan in rheumatoid arthritis by ultrasonography? A real life experience.
2017 ·PubMed ·Sibel Zehra Aydın, Salih Pay, Nevsun İnanç, Sevil Kamalı, Ömer Karadağ, Paul Emery, Maria Antonietta D’Agostino
5
15
Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study breakdown →
2016 ·Annals of the Rheumatic Diseases ·Maxime Dougados, Désirée van der Heijde, Ying‐Chou Chen, Maria Greenwald, Edit Drescher, Jiajun Liu, Scott D. Beattie, Sarah Witt, Inmaculada de la Torre, C. Gaich, Terence Rooney, Douglas Schlichting, Stephanie de Bono, Paul Emery
301
16
Biologics in systemic lupus erythematosus: current options and future perspectives
2014 ·British Journal of Hospital Medicine ·Md Yuzaiful Md Yusof, Edward M Vital, Paul Emery
8
17
ASSESSMENT OF GLOBAL DISEASE ACTIVITY IN RA BY PATIENTS AND PHYSICIANS: CULTURAL DIFFERENCES ACROSS COUNTRIES IN THE METEOR DATABASE
2014 ·Data Archiving and Networked Services (DANS) ·(unknown), C.F. Allaart, Ron Wolterbeek, Claiton Viegas Brenol, Arun Chopra, (unknown), Paul Emery, Gianfranco Ferraccioli, (unknown), T. Huizinga, Jonathan Kay, (unknown), (unknown), (unknown), (unknown), Douglas J. Veale, (unknown)
1
18
Biological therapy for rheumatoid arthritis: where are we now?
2012 ·British Journal of Hospital Medicine ·(unknown), Paul Emery
3
19
Paediatric and Adolescent Rheumatology [213-214]
2009 ·Lara D. Veeken ·Paul Emery, Roy Fleischmann, Larry W. Moreland, Elizabeth C. Hsia, W. Xu, (unknown)
1
20
Window of opportunity in early rheumatoid arthritis: possibility of altering the disease process with early intervention.
2004 ·PubMed ·Mark Quinn, Paul Emery
155

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Désirée van der Heijde Breakdown of academic impact, for papers by T. Huizinga Breakdown of academic impact, for papers by Yehuda Shoenfeld Breakdown of academic impact, for papers by Josef S Smolen Breakdown of academic impact, for papers by Lars Klareskog Breakdown of academic impact, for papers by Iain B. McInnes Breakdown of academic impact, for papers by David Isenberg Breakdown of academic impact, for papers by Georg Schett Breakdown of academic impact, for papers by Gene G. Hunder Breakdown of academic impact, for papers by Frank C. Arnett
Rankless by CCL
2026